Temporary restraining order for Dr Reddy’s in US

NEW DELHI: Indian pharma major Dr Reddy’s Laboratories said on Saturday that a US District Court has issued a temporary restraining order on the sale and commercialisation of its generic Buprenorphine and Naloxone sublingual film in the American market.

It is indicated for treatment of opioid dependence. Dr Reddy’s said in a BSE filing that the company remains confident in its legal positions on this patent.

“The court order does not include a prohibition on commercial manufacturing of the product,” it added. The court has scheduled an expedited hearing of the preliminary injunction for June 28, and a ruling is expected soon thereafter, it added.